Physician profile
Harold Margolis
NPI 1104800986
$2,522.05
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $187 · 2021: $159 · 2022: $649 · 2023: $286 · 2024: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $444.53 | 2019-2024 | Evenity |
| Pfizer INC. | $270.87 | 2019-2022 | |
| Glaxosmithkline, LLC. | $256.08 | 2019-2023 | Shingrix |
| Amag Pharmaceuticals, INC. | $173.91 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $160.63 | 2019-2023 | |
| Genzyme Corporation | $144.84 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $129.68 | 2019-2023 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $124.96 | 2020 | |
| Celgene Corporation | $111.47 | 2019-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $108.56 | 2019 | |
| Genentech USA, INC. | $78.10 | 2022-2023 | Venclexta |
| Janssen Biotech, INC. | $69.57 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $55.78 | 2019-2023 | Imbruvica |
| Incyte Corporation | $50.29 | 2019-2022 | |
| Lilly USA, LLC | $43.72 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $37.78 | 2021-2022 | |
| Abbvie INC. | $36.16 | 2019-2020 | |
| Stemline Therapeutics INC. | $31.08 | 2022-2023 | Orserdu |
| Eisai INC. | $24.46 | 2019 | |
| Daiichi Sankyo INC. | $23.69 | 2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $20.75 | 2023 | Somatuline Depot, Onivyde |
| Mirati Therapeutics, INC. | $18.06 | 2023 | Krazati |
| Array Biopharma INC | $17.16 | 2019 | |
| Beigene USA, INC. | $15.92 | 2023 | Brukinsa |
| Shire North American Group INC | $15.48 | 2019 | |
| Biogen, INC. | $15.19 | 2021 | |
| Kite Pharma, INC. | $12.83 | 2022 | |
| Tersera Therapeutics LLC | $12.75 | 2022 | |
| Fortovia Therapeutics, INC. | $11.64 | 2019 | |
| Penumbra, INC. | $6.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.